focus -WSS

focus

author：Wikipedia 2025-10-02 20:52:33 - browse：1367

Matts Take Column Illustration — Molly Ferguson for STAT

The news that the weight loss drug Wegovy reduced the risk of heart attacks and strokes in overweight volunteers opens up the door to vastly expanded use of the drug and medicines like it, known as GLP-1 medicines.

That could have a big, positive impact on public health, and it will very likely swell the coffers of the pharmaceutical companies that make these medicines, including Wegovy’s maker, Novo Nordisk, and Eli Lilly, now the most valuable drug company in history thanks largely to hopes for its GLP-1, Mounjaro. These are medicines that could save lives, make money, and perhaps reshape our culture. But they are also, we are learning, not without risk.

So what’s next?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Mississippi candidates for statewide offices square off in party primaries

hotspot

WSS

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Why palliative psychiatry is worth discussing

Trump Jan. 6 attorney John Lauro is ex

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Alabama hospital puts IVF treatments on hold

entertainment

focus

entertainment

Medical records are filled with copy

In utero gene editing: an explainer

Cancer drug shortages should be causing more outrage

Medicare inequities exacerbate Puerto Rico’s health disparities

United colonoscopy coverage change 'may cost lives,' doctors say

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

South Korea begins evacuating thousands of Scouts from coastal campsite as tropical storm nears

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Boeing's 1st astronaut flight bumped into next year, more repairs needed

focus

With competition flaring, obesity drug hits goal in liver disease study

STAT readers on older presidents, polypills, Medicare, and more

Ed Silverman on new gene therapies, biosimilars, coffee, and more

6 phony surgeries that take placebo to the extreme

Democratic lawmaker calls for 'well

R1 RCM gets $5.8 billion buyout offer from private equity firm

hotspot

hotspot

focus

focus